10-Q: NeOnc Technologies: Advisory Fee Structure Updated, Faces Going Concern Doubt

NeOnc Technologies Holdings, Inc. has amended its advisory agreement with AFH Holding & Advisory, LLC, establishing a new annual fee structure based on fully diluted market capitalization, while the company continues to grapple with significant operating losses and substantial doubt regarding its ability to continue as a going concern.

Summary

• NeOnc Technologies Holdings, Inc. has entered into a Second Addendum to its Letter of Intent and Advisory Services Agreement with AFH Holding & Advisory, LLC (AFH).
• Effective January 1, 2025, AFH will receive an annual advisory fee of 2.5% of the Company's Fully Diluted Market Capitalization, determined as of December 31st each fiscal year.
• For 2025, this fee was calculated at approximately $4.55 million based on a closing share price of $8.27 and approximately 22.0 million fully diluted shares.
• The company reported a net loss of $14.24 million for the three months ended June 30, 2026, and $23.06 million for the six months ended June 30, 2026.
• As of June 30, 2026, the Company had cash of $1.97 million and an accumulated deficit of $135.81 million.
• The filing explicitly states substantial doubt regarding the Company's ability to continue as a going concern within one year of the issuance date.
• Significant increases in research and development expenses were noted, primarily due to expanded clinical trial activities for NEO100 and NEO212.
• The company raised approximately $15.1 million in gross proceeds from a PIPE financing in January 2026 and $5 million from Series A Convertible Preferred Stock issuance in June 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued substantial net losses, significant accumulated deficit, and explicit statements raising substantial doubt about its ability to continue as a going concern, despite recent financing activities.

Positives

• Secured $15.1 million in gross proceeds from a PIPE financing in January 2026 and $5 million from Series A Convertible Preferred Stock issuance in June 2026.
• Entered into a Second Addendum to its advisory agreement with AFH, clarifying future advisory fee structures.
• NEO100 has Orphan Drug and Fast Track designation from the FDA for glioblastoma.
• NEO212 has FDA authorization to proceed with Phase 2a/2b clinical trials for primary and secondary malignant brain cancers.
• The company is actively pursuing additional financing to mitigate going concern risks.
• Received grant income of $482,778 for the three months ended June 30, 2026, related to NIH STTR grants.

Negatives

• Reported a net loss of $14.24 million for the three months ended June 30, 2026, and $23.06 million for the six months ended June 30, 2026.
• Accumulated deficit reached $135.81 million as of June 30, 2026.
• The company explicitly states substantial doubt regarding its ability to continue as a going concern.
• Cash and cash equivalents were $1.97 million as of June 30, 2026, which may not be sufficient to fund operations for a full year.
• Significant increase in research and development expenses, up $1.97 million for the three months and $2.30 million for the six months ended June 30, 2026.
• Accrued restricted stock tax withholdings obligations increased significantly to $9.45 million as of June 30, 2026.
• A litigation settlement payable of $4.38 million related to Orient EuroPharma Co., Ltd. remains outstanding.
• Material weaknesses in internal control over financial reporting persist, with ongoing remediation efforts.

Risks

• The company has not generated revenue from product sales and expects to continue incurring operating losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern.
• The company's lead product candidates, NEO100 and NEO212, are still in clinical development, and there is no assurance they will receive regulatory approval or achieve market acceptance.
• The company relies on third-party suppliers and, in some cases, single-source suppliers, which could disrupt its operations.
• The company's ability to obtain additional financing on favorable terms, or at all, is uncertain.
• The company is subject to risks common to biopharmaceutical companies, including technological innovations, dependence on key personnel, protection of proprietary technology, and product liability.
• The company has significant accrued restricted stock tax withholding obligations ($9.45 million) that require timely remittance.
• The company has an outstanding litigation settlement payable of $4.38 million related to Orient EuroPharma Co., Ltd.
• Material weaknesses in internal control over financial reporting require ongoing remediation, which could impact the reliability of financial reporting.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as it advances its product candidates through development and seeks regulatory approval. The ability to continue as a going concern is dependent on raising additional capital and implementing strategies such as executing additional licensing contracts. Future capital requirements will depend on the costs of clinical trials, manufacturing, regulatory review, commercialization, intellectual property, headcount growth, and operating as a public company.

Management Comments

• The company's lead product candidate, NEO100, is in clinical trials treating glioblastoma and has Orphan Drug and Fast Track designation from the FDA.
• NEO212 has received FDA authorization to proceed with Phase 2a/2b clinical trials and may proceed under the FDA's accelerated approval pathway.
• The company has initiated steps to remediate material weaknesses in internal control over financial reporting, including engaging consultants, implementing a new ERP system, and hiring a Chief Accounting Officer.
• The company is actively taking steps to mitigate the substantial doubt about its ability to continue as a going concern, including pursuing additional financing.

Industry Context

StockSavvy.ai notes that NeOnc Technologies operates in the highly competitive and capital-intensive biopharmaceutical sector, where significant investment in R&D is required for drug development. The company's focus on CNS diseases, particularly glioblastoma, addresses a critical unmet medical need. However, the substantial operating losses and going concern warnings are common challenges for clinical-stage biotechs, highlighting the inherent risks and the critical need for successful clinical outcomes and continued funding.

Comparison to Industry Standards

• Biopharmaceutical companies at a similar clinical stage often face significant R&D expenses and net losses, as seen with NeOnc's $23.06 million loss for the first six months of 2026.
• The need for substantial future financing is a standard characteristic of the industry; companies like NeOnc often rely on multiple funding rounds (PIPEs, preferred stock, ATM offerings) to sustain operations until product commercialization.
• The pursuit of FDA designations like Orphan Drug and Fast Track (for NEO100) is a common strategy to expedite development and commercialization for rare diseases or critical unmet needs.
• The 'going concern' warning is a frequent occurrence for pre-revenue biotechs, underscoring the high-risk, high-reward nature of the sector. Companies like Moderna and BioNTech also faced similar challenges in their early stages before achieving commercial success.

Management Changes

Legal Proceedings

• A litigation settlement payable of $4,378,904 related to Orient EuroPharma Co., Ltd. remains outstanding, stemming from a terminated collaboration agreement.
• The company previously settled a vendor complaint for $600,000 plus interest, totaling $737,921 paid in February 2026.

Related Party Transactions

• AFH Holding & Advisory, LLC (owned by Executive Chairman and CEO Amir Heshmatpour) is entitled to an annual advisory fee of 2.5% of the Company's Fully Diluted Market Capitalization.
• As of June 30, 2026, $1,656,575 was accrued and payable to AFH for advisory services.
• The Company utilizes laboratory and patent maintenance services from the University of Southern California (USC), where Dr. Thomas Chen (Founder, Chief Medical Officer, Chief Scientific Officer) is a professor.
• As of June 30, 2026, $361,535 was accrued and payable to USC for laboratory and patent maintenance fees.
• The Company has a receivable from HCWG LLC of $138,247 for legal fees paid on its behalf.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues, substantial losses, and potential dilution from future capital raises.
• Creditors and suppliers may face uncertainty regarding timely payments given the company's liquidity challenges.
• Employees may experience uncertainty regarding job security due to the company's financial condition and potential need to scale back operations.
• The company's ongoing clinical trials and product development efforts are critical for future value creation for all stakeholders.

Next Steps

• The company intends to meet with the FDA to discuss the design of a potential Phase 3 clinical trial of NEO100.
• The company plans to advance NEO212 into Phase 2 clinical trials.
• The company is actively pursuing additional financing to mitigate going concern risks.
• The company is working to remediate material weaknesses in its internal control over financial reporting.

Key Dates

Recommendation

The company's persistent net losses, substantial accumulated deficit, and explicit statement of substantial doubt regarding its ability to continue as a going concern present significant risks. While recent financing provides some runway, the path to profitability and product commercialization remains highly uncertain and fraught with clinical and regulatory hurdles. The increased advisory fees, while clarified, represent a significant ongoing cost. Given these factors, a sell recommendation is warranted for risk-averse investors.

Keywords

NeOnc Technologies, Advisory Services Agreement, AFH Holding & Advisory, Fully Diluted Market Capitalization, Going Concern, Clinical Trials, NEO100, NEO212